InvestorsHub Logo
Followers 40
Posts 1920
Boards Moderated 0
Alias Born 11/08/2011

Re: Den post# 1508

Friday, 10/19/2012 3:26:17 PM

Friday, October 19, 2012 3:26:17 PM

Post# of 130513
What exactly does RBCC have to bring to the table of being in a JV with AMBS?

RBCC does not appear to be in a position to offer anything of value to AMBS - case in point, look at their latest financials: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8819869

Items to note regarding RBCC:
Assets = $25k in cash and inventory of $35k (attributed to their Father Fish Aquarium line of business)
Operating Expenses in 1st quarter = $667k - primarily attributed to G&A expenses (the company has ONE employee!)
Patrick Brown, CEO, has no relavent bioscience experience.
The Company has no tangible assets related to the bioscience industry.
The Company has a negative working capital of $273,944
The Company entered into a toxic convertible note with Glendive Investments - a Polish offshore account created by the late JT Cloud and his brother inlaw, Robert Federowicz with the help of Kathleen Delaney - the same guys who brought you these SEC suspended companies: GSLO, EHSI, EVSO, GAEC, SSLR, and ONYX.

RBCC's website makes broad statements about how it could develop cures for Autism, Stem Cell Research breakthroughs, Parkinson's disease, claims of "spearheading the most innovative scientific and medical breakthroughs in the $84.6 billion global biotech industry", and "RBCC is joining the ranks of bioscience companies like Puma" - yet has no assets, personnel, money, or industry knowledge to even make such claims.